Abstract
Increasing efforts have been made for the development of antibody-directed, tumor-selective cytotoxic agents by coupling cytotoxic agents to antibodies to tumor-associated antigens on the tumor cell surface. Toxins and their subunits, anti-cancer drugs, and radioisotopes are used as the toxic agents for the antibody conjugates. This article discusses the current status of research on antibody conjugates with the enzymatic subunit A-chain of the plant toxin ricin and with the anti-cancer drug methotrexate focusing on the development of the methods of preparation of the conjugates having better biological profile.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
